Beovu (brolucizumab-dbll) / Novartis - LARVOL DELTA

Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis. (PubMed, Ophthalmol Retina) - "This global pharmacovigilance study revealed variability in ocular AE reporting across anti-VEGF agents. Brolucizumab showed the strongest signal for intraocular inflammation, while aflibercept showed the highest signal for endophthalmitis. Continued real-world monitoring is warranted to define evolving safety profiles across anti-VEGF agents."

Adverse events • Journal • Age-related Macular Degeneration • Diabetic Macular Edema • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Uveitis • Wet Age-related Macular Degeneration

An assessment of anti-VEGF drugs safety based on real-world data: from popularity to spontaneous reporting in eudravigilance database. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Anti-VEGF drugs often cause ocular ADRs when treating nAMD, which should be a clinical concern. To reduce the risk of adverse reactions, clinicians should closely monitor patients using these drugs."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China. (PubMed, BMJ Open) - P4 | "The study results will be submitted to a peer-reviewed journal and presented at both local and international congresses. NCT06498050."

Journal • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Multimodal Imaging to Assess Disease Activity and Predict Fluid Resolution in Patients with wAMD Treated with Brolucizumab: The IMAGINE Study. (PubMed, Ophthalmol Ther) - P4 | "Brolucizumab demonstrated effectiveness and safety in a real-world wAMD cohort, aligning with findings from randomized trials. Although no predictive biomarkers were identified, results emphasize the role of multimodal imaging in guiding individualized treatment strategies and highlight variability in patient responses."

Journal • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-World Outcomes in Eyes with Neovascular AMD Switched from Brolucizumab to Faricimab: A TRUCKEE Study Analysis: From Brolucizumab to Faricimab: A TRUCKEE Study Analysis. (PubMed, Am J Ophthalmol) - No abstract available

Journal • Real-world evidence • Wet Age-related Macular Degeneration

Anti-VEGF: Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema (clinicaltrials.gov) - P=N/A | N=38 | Completed | Sponsor: Benha University

New trial • Diabetic Macular Edema • Ophthalmology

Consensus of Expert Recommendations for the Safe Administration of Brolucizumab in Neovascular Age-related Macular Degeneration. (PubMed, Korean J Ophthalmol) - "In conclusion, this consensus recommendations emphasized the importance of the evidence-based and patient-centered stepwise approaches that should be considered when prescribing brolucizumab to patients with nAMD. This is not an absolute guideline, and the management should be adapted according to the ophthalmic conditions and the patients' opinions after thorough discussions."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Uveitis • Vasculitis • Wet Age-related Macular Degeneration

Novel anti-VEGF scFv antibodies with superior in vitro and in vivo activities. (PubMed, Sci Rep) - "The activities of the variants were compared to bevacizumab, ranibizumab and brolucizumab with VEGF bioassay. scFv1 inhibits in vitro angiogenesis and binds selectively to all VEGFA isoforms. The engineered anti-VEGF scFv1, is a promising therapeutic candidate for AMD treatment."

Journal • Preclinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events. (PubMed, J Clin Pharmacol) - "Although brolucizumab showed no significant disproportionality, interpretation requires caution because of limited data. Our findings underscore the importance of continued pharmacovigilance and hypothesis-driven investigations to ensure the safe use of anti-VEGF therapies."

Journal • Cardiovascular • Myocardial Infarction

Genetic Factors Associated with Intraocular Inflammation After Brolucizumab Administration in Patients with Exudative Age-Related Macular Degeneration. (PubMed, Genes (Basel)) - "After adjusting for confounding factors, the T allele remained significantly associated with protection against IOI (p = 0.028, 95% confidence interval: 0.098-0.88). The T allele of the CETP gene, a risk allele for AMD and the protective allele for atherosclerosis, may be associated with protection against IOI after brolucizumab administration in eyes that have exudative AMD."

Journal • Age-related Macular Degeneration • Atherosclerosis • Cardiovascular • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Vasculitis • Wet Age-related Macular Degeneration

Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials. (PubMed, BMC Ophthalmol) - "Compared with monotherapy, combination therapies using anti-VEGF agents and PDT provide significant visual and anatomical advantages in managing PCV. These treatments are associated with improved efficacy and a reduced treatment burden while maintaining favorable safety profiles. However, further standardization of protocols and evaluation of long-term cost-effectiveness are crucial for improving clinical practice applications."

Clinical • Journal • Monotherapy • Retrospective data • Review • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Punctate Hyperfluorescence as a Favorable Predictive Factor for Treatment Response Following a Switch to Brolucizumab for Patients with Aflibercept-Refractory Neovascular Age-Related Macular Degeneration. (PubMed, J Clin Med) - " Switching to brolucizumab may be an effective treatment option for patients with aflibercept-refractory nAMD. Punctate hyperfluorescence may serve as a favorable prognostic factor following a switch to brolucizumab."

Biomarker • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Initial Response After Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration. (PubMed, J Clin Med) - "The drugs used prior to switching were faricimab in five eyes, brolucizumab in six eyes, and aflibercept 2 mg in 91 eyes, with a mean interval of 63.7 ± 20.0 days from the last pre-switch injection and 64.9 ± 20.1 days to the first post-switch visit. No ocular or systemic adverse effects were observed. As an initial response to switching to aflibercept 8 mg in a real-world setting, SRF and IRF completely resolved in approximately half of the patients, and sPED resolved in about 30% of cases."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Immediate and Short-Term Intraocular Pressure Changes Following Intravitreal Injection and Associated Factors. (PubMed, J Clin Med) - "Aflibercept use, high baseline IOP, glaucoma history, and absence of prior vitrectomy were associated with greater IOP elevation. Careful monitoring and attention to injection volume may be warranted, particularly in high-risk patients."

Journal • Glaucoma • Ophthalmology

Re: Brown et al.: MERLIN: Two-year results of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. (Ophthalmology. 2025;132:131-140). (PubMed, Ophthalmology) - No abstract available

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy. (PubMed, Ophthalmol Ther) - "In our cohort of patients with PNV, switching to brolucizumab demonstrated a significant anatomical response, leading to a reduction in exudative features. While BCVA remained stable, the number of brolucizumab injections required to resolve SRF emerged as a predictor of final visual outcome, suggesting that an earlier switch in non-responders might optimize anatomical results. The safety profile of brolucizumab in this study was favourable, with no severe inflammatory adverse events reported."

Journal

Functional and anatomic outcomes of brolucizumab in adults with neovascular age-related macular degeneration - The OCTOPUS cohort study. (PubMed, J Fr Ophtalmol) - "CNV lesion size as assessed by OCTA decreased with brolucizumab, which also led to vision gains and better anatomic outcomes."

Clinical • Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Sterile Intraocular Inflammation Following Intravitreal Injections: Pathogenesis, Clinical Features, and Management. (PubMed, Int Ophthalmol Clin) - "Epidemiologic data show variable incidence across agents, with brolucizumab demonstrating higher rates of inflammation compared with ranibizumab or aflibercept. Treatment includes corticosteroids and discontinuation of the offending agent, with rare cases requiring surgical intervention. As the therapeutic landscape expands, heightened awareness and standardized evaluation of postinjection inflammation are critical to improving safety and preserving vision."

Journal • Review • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis

Effectiveness and Safety of Intravitreal Brolucizumab for Diabetic Macular Edema After Vitrectomy: A Before-and-After Study at a Specialized Center in Japan. (PubMed, Clin Ophthalmol) - "If CST did not improve after the last IVBr injection, treatment was switched to intravitreal triamcinolone acetonide injection (IVTA), sub-Tenon's triamcinolone acetonide (STTA) injection, or intravitreal faricimab (IVFa)...Our findings demonstrated partial efficacy of IVBr in managing DME in vitrectomized eyes. However, variable responses often necessitate supplementary treatments to achieve therapeutic goals."

Journal • Diabetes • Diabetic Macular Edema • Inflammation • Metabolic Disorders • Ophthalmology

Comparison of ocular blood flow changes at 30 minutes after intravitreal injection of faricimab, brolucizumab, and aflibercept 2 mg for neovascular age-related macular degeneration. (PubMed, Retina) - "Ocular blood flow significantly decreased 30 minutes post-injection in faricimab-, brolucizumab-, or aflibercept-treated eyes with nAMD. Brolucizumab-treated eyes showed a significantly greater reduction in choroidal blood flow than aflibercept-treated eyes."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Disease control, visual and anatomic outcomes at week 48 of brolucizumab treatment in patients with previously suboptimal anatomically controlled neovascular age-related macular degeneration - The SWIFT study. (PubMed, J Fr Ophtalmol) - P3 | "In patients with refractory nAMD, brolucizumab allowed control of disease activity for up to 41.0% of patients, with visuals gains, anatomical improvements and extended treatment interval, despite poor response and discontinuation for some patients in addition to a 9.8% rate of IOI."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and Safety of Brolucizumab in Neovascular Age‑related Macular Degeneration – A Real-world Study (SOE 2025) - "In this real-world study, brolucizumab demonstrated its effectiveness in maintaining CDVA while significantly improving key anatomical parameters, consistent with the HAWK and HARRIER trials. These findings support the use of brolucizumab in clinical practice, but highlight the need for careful patient selection and close monitoring for adverse events."

Clinical • Real-world • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-world outcomes, including intraocular inflammation, after intravitreal brolucizumab for diabetic macular edema. (PubMed, Jpn J Ophthalmol) - "IOI developed in four of 56 (7.1%) eyes and responded well to prompt steroid therapy after 1.5 years of IVBr use for DME. BCVA and CMT improved at all evaluation time points. With an average of 3.8 IVBr injections per year, IVBr showed long-term efficacy for DME in the real-world setting, although the occurrence of IOI should be monitored."

Journal • Real-world evidence • Diabetic Macular Edema • Inflammation • Ocular Inflammation • Ophthalmology

Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review. (PubMed, Medicine (Baltimore)) - "Brolucizumab is one of the latest anti-VEGF agents clinically proven to treat nAMD after on-label agents namely, ranibizumab and aflibercept. However, it also has a risk of intraocular inflammation. This review summarizes the evidence for brolucizumab in the treatment of nAMD."

Journal • Review • Age-related Macular Degeneration • Cardiovascular • Coronary Artery Disease • Macular Degeneration • Oncology • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Brolucizumab clinical and safety outcomes in a neovascular age-related macular degeneration national database: Fight Retinal Blindness Spain (FRB Spain). (PubMed, Eye (Lond)) - "In this series BRO achieves an extension in the treatment intervals in half of the patients which require frequent reinjections (<8 weekly), reducing MNV activity in a third of this specific difficult-to-treat subgroup. The adverse event rates described are consistent with other cohorts and need to be considered to inform treatment decisions in case-by-case discussions."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration